Abstract
Aging has become a major health care problem and socio-economic burden worldwide. Myocardial infarction (MI) is the major killer worldwide and coronary reperfusion is the major form of acute post-MI therapy. The aging population is increasing, and with it, morbidity and mortality due to impaired healing after ST-segment elevation MI (STEMI) and its consequences. Optimal healing of the wounded heart is critical for preservation of structural and functional integrity of the pumping chambers, survival, and a favorable outcome irrespective of age. Although STEMI is more prevalent in the elderly and impaired healing during aging may promote adverse remodeling and thereby jeopardize outcome, there is an information gap on post-STEMI healing and its therapy in the elderly. Current therapies during post-STEMI healing are aimed primarily at the < 65 age-group and preclinical studies tend to test drugs in mostly young animals. Therapies over the last decade have improved post-MI survival mainly in patients aged < 65 years. Novel healing-specific proteins may provide potential targets for improving healing and limiting adverse remodeling of the post-STEMI heart in the elderly, thereby improving outcome.
Keywords: Aging, ST-segment elevation myocardial infarction, ventricular remodeling, extracellular matrix, healing-specific proteins, secretory leucocyte protease inhibitor, osteopontin, secreted protein acidic and rich in cysteine
Current Drug Targets
Title: Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Volume: 9 Issue: 4
Author(s): Bodh I. Jugdutt
Affiliation:
Keywords: Aging, ST-segment elevation myocardial infarction, ventricular remodeling, extracellular matrix, healing-specific proteins, secretory leucocyte protease inhibitor, osteopontin, secreted protein acidic and rich in cysteine
Abstract: Aging has become a major health care problem and socio-economic burden worldwide. Myocardial infarction (MI) is the major killer worldwide and coronary reperfusion is the major form of acute post-MI therapy. The aging population is increasing, and with it, morbidity and mortality due to impaired healing after ST-segment elevation MI (STEMI) and its consequences. Optimal healing of the wounded heart is critical for preservation of structural and functional integrity of the pumping chambers, survival, and a favorable outcome irrespective of age. Although STEMI is more prevalent in the elderly and impaired healing during aging may promote adverse remodeling and thereby jeopardize outcome, there is an information gap on post-STEMI healing and its therapy in the elderly. Current therapies during post-STEMI healing are aimed primarily at the < 65 age-group and preclinical studies tend to test drugs in mostly young animals. Therapies over the last decade have improved post-MI survival mainly in patients aged < 65 years. Novel healing-specific proteins may provide potential targets for improving healing and limiting adverse remodeling of the post-STEMI heart in the elderly, thereby improving outcome.
Export Options
About this article
Cite this article as:
Jugdutt I. Bodh, Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets, Current Drug Targets 2008; 9 (4) . https://dx.doi.org/10.2174/138945008783954934
DOI https://dx.doi.org/10.2174/138945008783954934 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews FoxO3a Governs Early Microglial Proliferation and Employs Mitochondrial Depolarization with Caspase 3, 8, and 9 Cleavage During Oxidant Induced Apoptosis
Current Neurovascular Research Hyperpolarized Metabolic MR in the Study of Cardiac Function and Disease
Current Pharmaceutical Design Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience Mechanisms of Intimal Hyperplasia Learned from a Murine Carotid Artery Ligation Model
Current Vascular Pharmacology Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Genetics of Hypertrophic and Dilated Cardiomyopathy
Current Pharmaceutical Biotechnology Usefulness of 5 Minutes <sup>123</sup>I-mIBG Scan in Parkinson’s Disease and Heart Failure
Current Radiopharmaceuticals An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor
Current Drug Delivery Viral Infection - A Cure for Type 1 Diabetes?
Current Medicinal Chemistry Unfolded Protein Response as a Therapeutic Target in Cardiovascular Disease
Current Topics in Medicinal Chemistry Editorial [News in Therapy of Cardiomyopathy (Executive Editor: Giovanni Fazio)]
Current Pharmaceutical Design Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement
Current Cardiology Reviews High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology